Post-Market Surveillance for Medical Devices
Post-market surveillance (PMS) is the manufacturer’s ongoing, proactive system for collecting and analysing real-world data on a device’s performance, safety, and clinical benefit after it reaches the market — feeding findings back into risk management, design, labelling, and, where thresholds are met, regulatory reporting. Under EU MDR it is a named, structured system with defined outputs; under FDA’s framework the same intent is distributed across complaint handling, MDR reporting, and quality-system feedback requirements.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 21 LINKSSurveillance is the proactive half of the post-market obligation: it runs whether or not anything has gone wrong, and its output is a signal early enough to act on — not a tally of complaints already received.
06 · QUALITY MATURITY — POST-MARKET SURVEILLANCE FOR MEDICAL DEVICES, REACTIVE TO ADAPTIVE
Post-market data means complaints that arrived. Nothing is sought out, and quiet is read as good news.
A surveillance plan exists and reports are produced on schedule, but every input is passive and the report restates counts.
Proactive sources are actually used — literature, registries, similar-device data, user feedback — and the analysis looks for trends rather than reporting totals.
Findings change something: the risk file, the instructions, the design or the clinical evaluation, and the change is traceable to the finding.
Surveillance is a designed feedback loop with defined signals and thresholds, so a developing problem is detected while it is still small.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 4
Derived from the 4 standards SPEQ maps to this subject, across 3 regulatory bodies: FDA, ISO, EC.
RECORDS & OBJECTIVE EVIDENCE
- The post-market surveillance plan, with its proactive as well as reactive sources
- Periodic surveillance reporting at the interval the device’s class requires
- Trend analysis with the method stated, not only the counts
- The link from a surveillance finding to a change in the risk file, labelling, design or clinical evaluation
- Inputs from literature, registries and similar devices, with search strategies
COMMON INSPECTION FINDINGS
- A surveillance system fed only by complaints that happened to arrive
- Reports produced on time that restate volumes and identify no signal
- Trends visible in the data with no corresponding assessment or action
- Surveillance findings never reaching the risk management or clinical evaluation files
- Literature and registry searches described in the plan but not performed
Why Post-Market Data Matters
Premarket clinical evidence, however rigorous, is generated on a limited population under controlled conditions over a bounded time period. Post-market surveillance exists because real-world use — a broader, less controlled population, longer duration, off-label use patterns, interaction with other devices and drugs — routinely surfaces safety or performance signals that premarket evidence could not have captured.
EU MDR requires manufacturers to establish, document, implement, maintain, and continuously update a PMS system proportionate to the device’s risk class, as an explicit, standalone regulatory obligation rather than an implicit extension of complaint handling.
PMS System Components
A PMS system typically draws on complaints, service and repair data, literature surveillance, registries, user feedback, and — for higher-risk devices — Post-Market Clinical Follow-up (PMCF) studies designed specifically to confirm continued safety and performance in real-world use. Data feeds a PMS report or, for higher-risk devices under EU MDR, a Periodic Safety Update Report summarising conclusions and any resulting actions.
PMS findings route back into the device’s risk management file and clinical evaluation, closing the loop between real-world evidence and the premarket risk-benefit conclusions that justified the device’s original approval or CE mark.
PMS vs. Vigilance Reporting
PMS is the broad, continuous surveillance system; vigilance/incident reporting is the specific, threshold-triggered obligation to report serious incidents and field safety corrective actions to regulators within defined timelines. PMS is where signals are gathered and trended; vigilance reporting is what happens when a specific signal meets a reportability threshold — the two are connected but operate on different cadences and different triggers.
Regulatory Comparison
FDA does not use the EU MDR’s single named “PMS system” construct in the same structured way, but achieves an analogous outcome through complaint-handling requirements, Medical Device Reporting (MDR) under 21 CFR 803, and, for certain devices, post-approval or post-market surveillance study orders — the underlying expectation of ongoing real-world monitoring and feedback into the quality system is consistent across both frameworks even where the documentation architecture differs.
SPEQ interpretation: organisations selling into both the EU and US markets generally benefit from designing one integrated PMS process that satisfies MDR’s explicit system requirement and produces the data FDA’s complaint-handling and MDR-reporting obligations require, rather than running two disconnected regional processes over the same underlying real-world data.
FREQUENTLY ASKED
Is post-market surveillance the same as pharmacovigilance?
They are analogous concepts applied to different product types — PMS applies to medical devices, pharmacovigilance to medicinal products — and while both involve ongoing real-world safety monitoring, the specific regulatory frameworks, reporting thresholds, and terminology differ.
Does every device need Post-Market Clinical Follow-up (PMCF)?
PMCF expectations scale with device risk class under EU MDR; higher-risk devices generally require an active PMCF plan, while for some lower-risk, well-established devices a justified rationale for a more limited PMCF approach may be acceptable — but PMS itself, at some level, applies to essentially all devices on the market.
Who within an organisation typically owns post-market surveillance?
Ownership commonly sits with quality or regulatory affairs, but a functioning PMS process pulls in inputs from complaint handling, clinical affairs, and often customer-facing service functions — it is rarely a single-department activity in practice, even when one function is formally accountable for the system.